Lenalidomide Plus Rituximab (R) in Non Follicular NHL

Indolent Non Hodgkin Lymphoma Clinical Trial

Official title:

Phase II Study of Lenalidomide in Combination With Rituximab (R) for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL).

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT01830478
• Other study ID #: INFL08
• Status: Unknown status
• Phase: Phase 2
• First received: April 5, 2013
• Last updated: April 9, 2013
• Start date: April 2009
• Est. completion date: October 2014

Study information

• Verified date: April 2013
• Source: Gruppo Italiano Studio Linfomi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether lenalidomide in association with rituximab is effective in the treatment of patients with indolent non follicular NHL relapsed after >=2, but less than 4 prior lines of (immuno)chemotherapy.

Description:

Single arm, multicenter, open-label study divided in two phases: 1. Induction phase; 2. Follow-up phase. Enrolled patients will start the induction phase and receive the courses of R-Lenalidomide. At the end of the third cycle of R-Lenalidomide (week 12 of the study), the patients will be evaluated for tumor response (complete assessment); the patients with Progressive Disease (PD) will be withdrawn of the study. Two weeks after the end last courses of R-Lenalidomide (week 26 of the study) patients will be evaluated for tumor response (complete assessment). Patients with Complete Response (CR) and Partial Response (PR), and with a stable disease will undergo the follow up phase, while patients with PD will be withdrawn of the study.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 44
• Est. completion date: October 2014
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histological confirmed diagnosis of B-Cell non follicular NHL according to REAL/WHO Classification: small lymphocytic lymphoma, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, nodal marginal zone lymphoma, splenic marginal zone lymphoma, extranodal non-gastric marginal zone lymphoma

• Availability of tissue biopsy mandatory when suspected pathological sites (nodal or extranodal) are easily accessible and in presence of extranodal non-gastric marginal or nodal marginal zone lymphoma diagnosis. In the other cases bone marrow biopsy, when representative, may be considered sufficient for defining lymphoma histotype

• Disease relapsing after >=2, but less than 4 prior lines of (immuno)chemotherapy. At least one of previous treatment had to include rituximab

• Presence of at least one of the following criteria for the definition of active disease: systemic symptoms, bulky disease, progressive marrow failure and/or splenomegaly and/or lymph adenopathy

• Age 18-75

• Life expectancy > 6 months

• Eastern Cooperative Oncology Group (ECOG) <=2

• Left ventricular ejection fraction (LVEF) >=45%

• Creatinine clearance >= 50 mL/min calculated by Cockcroft-Gault estimation; patients with creatinine clearance >= 30 and < 50 mL/min, at physician discretion could enter the study starting at lenalidomide dose level -2 (10 mg)

• Total bilirubin up to 2 x upper limit of normal(ULN). Total bilirubin values higher than 2 x ULN are admitted if related to localization of the disease

• Alkaline phosphatase up to 2 x ULN and transaminases up to 3 x ULN

• Female and male patients must agree to participate in pregnancy prevention program signing informed Consent (paragraph 5.4.)

• Written informed Consent

Exclusion Criteria:

• Previously untreated patients

• Patients with diagnosis of typical Chronic Lymphocytic Leukemia (CLL)

• Women and men not agreeing to take adequate contraceptive precautions during and for at least 4 weeks after cessation of therapy

• Pregnant or lactating women

• History of other malignancies within 3 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer, low grade, early stage localized prostate cancer treated surgically with curative intent, good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent

• Active bacterial, viral or fungal infection requiring systemic therapy

• Concurrent co-morbid medical condition which might exclude administration of therapy

• Cardiac insufficiency (NYHA grade III/IV)

• Myocardial infarction within 6 months of entry on the study

• Severe chronic obstructive pulmonary disease with hypoxemia

• Severe diabetes mellitus difficult to control with adequate insulin therapy

• Hypertension that is difficult to control

• Creatinine clearance < 30 mL/min calculated by Cockcroft-Gault estimation

• Absolute neutrophil count (ANC) <= 1 x 109/L, unless due to lymphoma involvement and not responding to 5 days of Granulocyte colony-stimulating factor (G-CFS) treatment

• Platelets count <=75.000/mm3, unless due to lymphoma involvement

• HIV and Hepatitis B virus (HBV) positivity

• Hepatitis C virus (HCV) positivity in presence of high level of virus replication and Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) > x 2.5 ULN

• Central nervous system (CNS) involvement by lymphoma

• Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins

• Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

Related Conditions & MeSH terms

• Indolent Non Hodgkin Lymphoma
• Lymphoma
• Lymphoma, Non-Hodgkin

Intervention

Drug:
• Lenalidomide
Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
• Rituximab
Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles

Locations

Country	Name	City	State
Italy	Centro Oncologico Modenese	Modena	MO

Sponsors (1)

Lead Sponsor	Collaborator
Gruppo Italiano Studio Linfomi

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the efficacy	Evaluate the efficacy in term of Overall Response Rate (Complete Response + Partial Response) and Tumour Control Rate (Complete Response + Partial Response + Stable Disease)	Two weeks after the completion of Rituximab + Lenalidomide
Secondary	Assess the safety	The safety will be evaluated on the basis of recorded toxicities graded on a scale of 1 to 5 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0	From start of treatment for all follow up period (18 months)